---
title: "TIANYU PHARM issued a profit forecast, expecting a net profit attributable to the parent company of 130 million to 180 million yuan in the first half of the year, a year-on-year increase of 144.29%-238.25%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248569525.md"
description: "TIANYU PHARM expects its net profit attributable to shareholders in the first half of 2025 to be between 130 million yuan and 180 million yuan, a year-on-year increase of 144.29%-238.25%. The net profit after deducting non-recurring gains and losses is expected to be between 121 million yuan and 171 million yuan, a year-on-year increase of 92.79%-172.45%. The company has improved the revenue scale and gross profit growth of its non-sartan active pharmaceutical ingredients and intermediates business, CDMO business, and formulation business through measures such as optimizing product structure, improving market layout, and strengthening cost control"
datetime: "2025-07-15T09:17:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248569525.md)
  - [en](https://longbridge.com/en/news/248569525.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248569525.md)
---

# TIANYU PHARM issued a profit forecast, expecting a net profit attributable to the parent company of 130 million to 180 million yuan in the first half of the year, a year-on-year increase of 144.29%-238.25%

According to the Zhitong Finance APP, TIANYU PHARM (300702.SZ) disclosed its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of the listed company to be between 130 million yuan and 180 million yuan, a year-on-year increase of 144.29%-238.25%; the net profit after deducting non-recurring gains and losses is expected to be between 121 million yuan and 171 million yuan, a year-on-year increase of 92.79%-172.45%.

During the reporting period, the company effectively enhanced the revenue scale and gross profit growth of its non-sartan raw materials and intermediates business, CDMO business, and formulation business through measures such as optimizing product structure, improving market layout, and strengthening cost control

### Related Stocks

- [300702.CN](https://longbridge.com/en/quote/300702.CN.md)

## Related News & Research

- [China’s Jinlihua Electric Soars by Limit After Unveiling Plan to Foray Into Commercial Aerospace Field](https://longbridge.com/en/news/287036981.md)
- [The 'Elon Musk Effect' Could Send SpaceX Stock Into Wild Swings After IPO Even If Starlink Makes 'Billions' In Profit, Warns Expert](https://longbridge.com/en/news/286923494.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [Apple Flavor to Buy NovoSana’s China Assets for Up to USD66 Million in Health Supplements Push](https://longbridge.com/en/news/287039106.md)